Podium to Practice: ESMO® 2025 – GI: CheckMate 8HW
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA29 – Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): new results from CheckMate 8HW
This program has been made possible through unrestricted support from Amgen.
Studies/trials discussed:
LBA29 – Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): new results from CheckMate 8HW
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.